You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Digestive tract conditions
  5. Inflammatory bowel disease

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

  • Technology appraisal guidance
  • Reference number: TA352
  • Published:  26 August 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination document

Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination document Crohn's disease (moderate to severe) - vedolizumab: final appraisal determination document
10 July 2015
(544.15 Kb 38 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 08 July 2015

Back to top